The Medicines Company's Angiomax patent ruled invalid

4 July 2015

The US Court of Appeals for the Federal Circuit Court has ruled against The Medicines Company (Nasdaq: MDCO) in its anticoagulant Angiomax (bivalirudin) patent litigation with Hospira (NYSE: HSP), which is in the process of being acquired by Pfizer (NYSE: PFE).

In its ruling on Thursday (July 2), the Federal Circuit held that US Patent Nos 7,582,727 (the ‘727 patent) and 7,598,343 (the ‘343 patent) are invalid. Industry watchers has been concerned that the company’s shares would see a drop on a negative decision, but in fact the stock jumped 10.4% to $31.28 by close of trading. US markets were closed on Friday for the July 4 public holiday.

Litigation background

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK